<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0508245727
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1987
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SOLU CORTEF AOV 250 mg powder and solvent for solution for injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        HYDROCORTISONE SODIUM SUCCINATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular and intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        16.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pfizer Manufacturing Belgium N.V." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pfizer Manufacturing Belgium N.V.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H02AB09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Solu-Cortef is a medicine of the family of glucocorticoids.</p><p><em>&nbsp;</em></p><p>Hydrocortisone inhibits local inflammatory effects (fever, swelling, pain, redness), and hypersensitivity reactions. It also affects a number of organs and metabolic processes in the body. For this reason, it is used in the treatment of a wide range of diseases, including:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic diseases including asthma and allergies to medicinal products;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin diseases;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain respiratory diseases;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain serious diseases of the blood;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; poor functioning of the adrenal cortex;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain kinds of shock.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Solu-Cortef:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to the active substance or any of the other ingredients of this medicine listed in section 6.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in case of a fungal infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are due to have certain vaccines, called attenuated live vaccines, administered. At certain doses, corticosteroids can suppress the immune system.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before using Solu-Cortef:</p><p>You must remain under regular medical supervision throughout your treatment with Solu-Cortef:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are part of one of these special risk groups:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children and adolescents: a slowdown in growth is possible in cases of prolonged treatment</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetic patients: there may be an increased need for insulin or oral antidiabetics</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with high blood pressure (hypertension)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with bone decalcification (osteoporosis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with gastrointestinal disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients predisposed to, or suffering from thromboembolic disorders (blood clots obstructing the blood vessels)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with severe muscle weakness (myasthenia gravis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients whose kidneys function poorly</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with mood disorders</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients who have or have had tuberculosis in the past</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with herpes or shingles who also have problems with the eyes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with Epilepsy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have or have ever had disease or infection of the heart.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from a deficiency in thyroid hormone (hypothyroidism) or liver disease (cirrhosis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a tumour of the adrenal gland (known as pheochromocytoma), tell your doctor before treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from traumatic brain injury, as you must not use systemic corticosteroids.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If long-term treatment with this medication is required.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience symptoms such as severe and generalised weakness, a drop in blood pressure when moving from a lying-down to a standing position, depressed mood or major stress, talk to your doctor. Nervous disorders (epidural lipomatosis), eye disorders (including central serous chorioretinopathy, a disease of the retina) have also been reported.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have any biological tests planned: tell your doctor that you are taking this medicine before your tests.</p><p>&middot;&nbsp;&nbsp;&nbsp; &nbsp; If you are already taking other medicines. Please also read the section &quot;Other medicines and Solu-Cortef&quot;.</p><p>&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;If hydrocortisone is administered to a premature baby, it may be necessary to monitor heart function and structure.</p><p><strong>&nbsp;</strong></p><p>Contact your doctor if you experience blurred vision or any other visual disturbances.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Solu-Cortef</strong></p><p>Please tell your doctor or pharmacist if you are taking, have recently taken, any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p>Certain medicinal products can affect the action of Solu-Cortef and vice versa. Consult your doctor if you are taking any of the following medicines:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain antibiotics (rifampicin, fluoroquinolones and macrolides such as erythromycin);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain other medicines may increase the effects of Solu-Cortef, and your doctor may decide to monitor you closely if you take these medicines, which include certain antivirals (ritonavir, indinavir) and pharmacokinetic potentiators (cobicistat), used in the treatment of HIV infection,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain antifungals (medicines used in the treatment of fungal infections) (for example ketoconazole);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anticoagulants (medicines that slow down or prevent blood clotting);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antiepileptics (medicines used to treat epilepsy) (for example phenobarbital, carbamazepine and phenytoin);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antidiabetics (medicines used to treat diabetes), as there may be a need for increased doses of insulin or oral hypoglycaemic agents;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain diuretic medicines (used to increase the elimination of urine);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain anti-inflammatories (salicylates). The combination of glucocorticoids and certain kinds of anti-inflammatory agents can increase the risk of gastrointestinal disorders;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glucocorticoids suppress the immune system. Certain vaccinations are therefore contraindicated;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients who suffer from severe muscle weakness (myasthenia gravis), the simultaneous use of corticosteroids and cholinesterase inhibitors such as neostigmine and pyridostigmine can trigger a myasthenic crisis;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to combat hypertension (high blood pressure);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the toxicity of cardiac glycosides (medicines used for the heart, for example digoxin) can be increased when corticosteroids are used at the same time;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oestrogens (including oral contraceptives containing estrogen): Estrogen may increase the effects of hydrocortisone. It may be necessary to adjust the dose of Solu-Cortef if oestrogens are added or removed from the treatment plan;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; corticosteroids can partially suppress the effect of certain medicinal products used in anaesthesia, particularly curare-based neuromuscular blockers;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; corticosteroids may increase the side effects of sympathomimetics, such as salbutamol (a medicine used to treat asthma, among other conditions);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines, including barbiturates, phenylbutazone, and methotrexate.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The efficacy of Coumarin anticoagulants may be enhanced by concurrent corticosteroid therapy and close monitoring of the INR or prothrombin time is required to avoid spontaneous bleeding.</p><p>&nbsp;</p><p><strong>Solu-Cortef with food and drink</strong></p><p>Not applicable.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>This medicine may only be used during pregnancy when absolutely necessary. If you get pregnant while taking this medicine, tell your doctor immediately.</p><p>&nbsp;</p><p>This medicine must not be used while breast-feeding, unless your doctor has told you otherwise. Corticosteroids are excreted in human milk.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Ability to drive and use machines</strong></p><p>While vision problems occur only rarely as a side effect, you should be aware that they are a possibility and should exercise due care if you must drive a vehicle and/or operate machinery.</p><p>&nbsp;</p><p><strong>Solu-Cortef contains sodium</strong></p><p>- Solu-Cortef 100 mg powder and solvent for solution for injection contains less than 1 mmol (23&nbsp;mg) of sodium per Act-O-Vial, i.e., it is essentially &ldquo;sodium-free&rdquo;.</p><p>- Solu-Cortef 250 mg powder and solvent for solution for injection contains 25.3&nbsp;mg of sodium (main ingedient of table/cooking salt) per Act-O-Vial. This is equivalent to 1.27% of the maximum recommended daily intake of sodium for an adult.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Solu-Cortef will be administered by intramuscular or intravenous injection, or by intravenous infusion.</p><p>The dose and duration of treatment depend on the characteristics of your illness. Your doctor will determine what dose of this medicine you should receive, and for how long. Always use this medicine exactly as your doctor has told you.</p><p>&nbsp;</p><p><strong>If you use more Solu-Cortef than you should</strong></p><p>Acute overdose with this medicine results in no immediately visible phenomena. However, chronic overdose brings about typical symptoms such as moon face, swelling and water retention.</p><p>If you have used too much Solu-Cortef, contact your doctor, pharmacist or the poison centre immediately.</p><p>&nbsp;</p><p><strong>If you forget to use Solu-Cortef</strong></p><p>As you will receive this treatment under close medical supervision, it is unlikely that a dose will be forgotten. However, if you think this is the case, tell your doctor or pharmacist.</p><p><strong>&nbsp;</strong></p><p><strong>If you stop using Solu-Cortef</strong></p><p>Your doctor will determine for how long you should continue to take this medicine. In the event of discontinuation of long-term treatment, medical monitoring is recommended and it will be progressively reduced before stopping. In this case, your doctor will check that your adrenal glands are producing enough corticosteroids. Signs of an insufficient quantity of corticosteroids are serious fatigue (asthaenia), dizziness when moving from a lying to a standing position (orthostatic hypotension) and depression.</p><p><strong><u>&nbsp;</u></strong></p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>If you belong to one of the particular at-risk groups, you will be monitored regularly by your doctor (see section 2 &quot;Warnings and precautions for use&quot;).</p><p>&nbsp;</p><p>In rare cases, this medicine can cause a serious, potentially fatal allergic reaction (anaphylaxis). If you experience a rapid onset of breathing difficulties, swelling of the face and throat, and general malaise (shock), <strong>contact a doctor immediately.</strong></p><p>&nbsp;</p><p>The side effects that may occur when using this medicine are the same as for all glucocorticoids. They rarely occur during treatments of short duration. The risk of undesirable side effects may increase when glucocorticoids are administered in high doses or over a long period. The main side effects that may occur are as follows, their frequency is unknown:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>infections and infestations</em>: masking of infections, reactivation of tuberculosis or other latent infections, opportunistic infections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>malignant and unspecified tumours (including cysts and polyps)</em>: Kaposi&#39;s sarcoma.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>immune system disorders</em>: allergic reactions (for example spasmodic contraction of the bronchi, laryngeal oedema, urticaria), altered cutaneous tests.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>endocrine disorders</em>: Cushing&#39;s syndrome (chronic obesity with swollen and red &ldquo;moon&rdquo; face), disturbances in the balance of operation between natural glucocorticoid-producing glands and glands controlled by these hormones, such as the pituitary (inhibition of the pituitary-adrenal axis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>metabolic and nutritional disorders</em>: sodium retention, fluid retention, potassium loss (which may lead to hypokalaemic alkalosis), sugar assimilation disorders (reactivation of latent diabetes mellitus, change in glucose tolerance).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>psychological disorders</em>: changes in mood or personality, euphoria, insomnia, severe depression, worsening of certain existing psychological problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>nervous disorders</em>: increased pressure in the skull, vertigo, seizures, epidural lipomatosis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>eye disorders</em>: cataract, glaucoma (with risk of injury to the ocular nerve), eye infections, protruding eyes (exophthalmos), risk of corneal perforation in cases of ocular herpes simplex, central serous chorioretinopathy (a disease of the retina), blurred vision.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>&nbsp;cardiac disorders</em>: congestive heart failure in at-risk patients, arrhythmia and cardiac arrest, thickening of the heart muscle (hypertrophic cardiomyopathy) in premature babies.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>vascular disorders</em>: formation of blood clots in the blood vessels (thrombosis), increase or decrease of blood pressure (hypertension or hypotension).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>blood disorders</em>: increase in the number of white blood cells in the blood (leukocytosis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>respiratory disorders</em>: pulmonary embolism (obstruction of a blood vessel in the lungs), &quot;gasping syndrome&quot; (a respiratory condition characterised by continuous gasping).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>gastrointestinal disorders</em>:<em> </em>stomach ulcer with risk of perforation and bleeding (haemorrhage), haemorrhage in the stomach, perforation of the intestines, inflammation of the pancreas or oesophagus.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>skin disorders</em>: small bleeds under the skin (petechiae), bruising, skin atrophy (thin and fragile skin), facial redness (facial erythema), increased sweating, acne, stretch marks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>muscle and bone disorders</em>: weakness, pain or muscle inflammation, bone decalcification (osteoporosis), necrosis (destruction of tissues) related to local rupture of blood vessels, osteonecrosis (destruction of bone tissue), fractures, slowed growth in children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>reproductive organ and breast disorders</em>: irregular periods.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>general disorders and administration site conditions: </em>delayed healing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>tests and analyses</em>: increased pressure in the eye, disorders related to the assimilation of sugars (decreased carbohydrate tolerance), increased need for insulin or blood sugar-lowering medicines in diabetics, loss of potassium, lack of nitrogen (negative nitrogen balance), loss of calcium, modification of results of liver function tests, weight gain.&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>lesions, intoxications and procedural complications</em>: compression fractures of the vertebrae, tendon tear (in particular in the Achilles tendon).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leucocytosis.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p><p><strong>&nbsp;</strong></p><p><strong>To Report side effects</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp; SFDA Call centre: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children<em>.</em></p><p>&nbsp;</p><p>Store below 30 &deg;C.</p><p><u>&nbsp;</u></p><p><u>Reconstituted solution</u>:</p><p>Keep away from light and freezing temperatures.</p><p>&nbsp;</p><p>Reconstituted solutions of Solu-Cortef powder and solvent for solution for injection in Act-O-Vial should be used immediately after reconstitution</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date, which is stated on the carton after &ldquo;EXP&rdquo;.&nbsp;The expiry date refers to the last day of that month</p><p>Shelf life:</p><p>- Solu-Cortef 100 mg powder and solvent for solution for injection (Act-O-Vial): 24 months.</p><p>- Solu-Cortef 250 mg powder and solvent for solution for injection (Act-O-Vial): 30 months.</p><p>&nbsp;</p><p>Do not throw away any medicines via waste water or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is hydrocortisone.</p><p>It is present in the form of hydrocortisone sodium succinate (133.67&nbsp;mg and 334.18&nbsp;mg), which are equivalent to 100&nbsp;mg and 250&nbsp;mg hydrocortisone respectively.<em><u> </u></em></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>Solu-Cortef 100&nbsp;mg and 250&nbsp;mg powder and solvent for solution for injection:</p><p>-Powder for solution for injection: (lower compartment of the Act-O-Vial): monosodium phosphate Monohydrate, Disodium phosphate anhydrous, Sodium Hydroxide. (see section 2 &ldquo;Solu-Cortef contains sodium&rdquo;).</p><p>-Solvent for solution for injection: (upper compartment of the Act-O-Vial): water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Solu-Cortef is made available for use as a powder and solvent for solution for injection in Act-O-Vial dual compartment vials, allowing simple and immediate preparation of the solution for injection. The reconstituted Solu-Cortef solution is for intravenous and intramuscular administration.

Packaging:
Solu-Cortef 100 mg and 250 mg powder and solvent for solution for injection - Act-O-Vial.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder: </strong></p><p>PFIZER S.A., Boulevard de la Plaine 17, 1050 Brussels, Belgium.</p><p>&nbsp;</p><p><strong>Manufacturer: </strong></p><p>Pfizer Manufacturing Belgium NV, Rijksweg 12, 2870 Puurs, Belgium.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                August 2021.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">سولوكورتيف هو دواء ينتمي لعائلة القشرانيات السكرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعمل هيدروكورتيزون على تثبيط الآثار الالتهابية الموضعية (الحمى، التورم، الألم، الاحمرار) وتفاعلات فرط التحسس. ويؤثر أيضًا على عدد من الأعضاء والعمليات الأيضية في الجسم. ولهذا السبب، يُستخدم في علاج مجموعة كبيرة من الأمراض، بما في ذلك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض الحساسية بما في ذلك الربو وحالات الحساسية تجاه المنتجات الدوائية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض الجلد؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أمراض الجهاز التنفسي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أمراض الدم الخطيرة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف عمل القشرة الكظرية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أنواع الصدمة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال سولوكورتيف</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه المادة الفعالة أو أي مكون آخر من مكونات هذا الدواء المدرجة في القسم ٦،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الإصابة بعدوى فطرية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان يجب أن تتلقى أنواعًا معينة من اللقاحات، التي يُطلق عليها اللقاحات الحية الموهنة، يمكن للستيرويدات القشرية، عند جرعات معينة، أن تضعف عمل الجهاز المناعي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال سولوكورتيف</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل استخدام سولوكورتيف:</p><p dir="RTL">يجب أن تظل خاضعًا لإشراف طبي منتظم طوال مدة علاجك بسولوكورتيف:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تنتمي لإحدى مجموعات الخطر الخاصة التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال والمراهقون: قد يحدث تأخر محتمل في النمو في حالات العلاج المُطول</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى المصابون بالسكري: قد تزداد الحاجة إلى الإنسولين أو مضادات السكري التي يتم تناولها عبر الفم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى المصابون بضغط الدم المرتفع (ارتفاع ضغط الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى المصابون بفقدان الكالسيوم من العظام (هشاشة العظام)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى المصابون بمرض معدي معوي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى الذين يكونون عرضة للاضطرابات الانصمامية الخثارية، أو يعانون منها (جلطات الدم التي تسد الأوعية الدموية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى المصابون بضعف العضلات الشديد (الوهن العضلي الوبيل)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى الذين يعانون من ضعف في وظائف الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى المصابون باضطرابات مزاجية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى المصابون أو الذين أصيبوا في السابق بالدرن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى المصابون بالحزام الناري أو الهربس النطاقي ولديهم مشكلات بالعينين كذلك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى المصابون بالصرع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا أو سبق أن أصبت بمرض أو عدوى بالقلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من قصور في هرمون الغدة الدرقية (قصور الدرقية) أو من مرض بالكبد (تليف الكبد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بورم في الغدة الكظرية (يُعرف باسم الفيوكروموسيتوما)، فأخبر طبيبك قبل العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من إصابة رضحية بالدماغ، نظرًا لأنك يجب ألا تستخدم الستيرويدات القشرية الجهازية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان العلاج طويل الأمد بهذا الدواء لازمًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بأعراض مثل الضعف الشديد والمُعمم أو هبوط في ضغط الدم عند الانتقال من وضع الاستلقاء إلى وضع الوقوف أو مزاج اكتئابي أو توتر كبير، فتحدث إلى طبيبك. لقد تم أيضًا الإبلاغ عن الإصابة بالاضطرابات العصبية (ورم شحمي فوق الجافية)، اضطرابات العين (بما في ذلك اعتلال المشيمية والشبكية المصلي المركزي، وهو مرض يصيب شبكية العين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخطط للخضوع لأي اختبارات بيولوجية: فأخبر طبيبك أنك تتناول هذا الدواء قبل الخضوع لاختباراتك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp; إذا كنت تتناول بالفعل أدوية أخرى. يُرجى أيضًا قراءة قسم &quot;الأدوية الأخرى وسولوكورتيف&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; <strong>&nbsp;&nbsp;</strong>إذا أعطي هيدروكورتيزون لطفل مبتسر، فقد يلزم مراقبة وظيفة القلب وبنيته.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تواصل مع طبيبك إذا أصبت بتغيم الرؤية أو أي اضطرابات أخرى في الرؤية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">يُرجى أن تخبر طبيبك أو الصيدلي إذا كنت تتناول حاليًا أو تناولت مؤخرًا أي أدوية أخرى، بما في ذلك الأدوية التي يتم الحصول عليها بدون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن تؤثر بعض المنتجات الدوائية على عمل سولوكورتيف والعكس صحيح. استشر طبيبك إذا كنت تتناول أيًا من الأدوية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أنواع المضادات الحيوية (ريفامبيسين، والفلوروكوينولونات، والماكروليدات مثل إريثرومايسين)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تزيد أدوية أخرى معينة من تأثيرات سولوكورتيف، وقد يقرر طبيبك مراقبة حالتك عن كثب إذا تناولت هذه الأدوية التي تتضمن بعض مضادات الفيروسات (ريتونافير، إندينافير) والعقاقير المعززة للحرائك الدوائية (كوبيسيستات) المستخدمة في علاج عدوى فيروس نقص المناعة البشرية (HIV)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض مضادات الفطريات (الأدوية التي تُستخدم في علاج العدوى الفطرية) (مثل كيتوكونازول)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات التخثر (الأدوية التي تبطئ أو تمنع تجلط الدم)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الصرع (الأدوية التي تُستخدم لعلاج الصرع) (مثل فينوباربيتال وكاربامازيبين وفينيتوين)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات السكري (الأدوية التي تُستخدم لعلاج السكري)، حيث قد تكون هناك حاجة إلى زيادة جرعات الإنسولين أو العوامل الخافضة للسكري التي يتم تناولها عبر الفم؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أنواع الأدوية المدرة للبول (تُستخدم لزيادة إفراز البول)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أنواع مضادات الالتهاب (الساليسيلات). يمكن أن يؤدي الجمع بين القشرانيات السكرية وأنواع معينة من العوامل المضادة للالتهاب إلى زيادة خطر الإصابة بالاضطرابات المعدية المعوية؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعمل القشرانيات السكرية على تثبيط الجهاز المناعي، ولذلك يُمنع استعمال بعض أنواع اللقاحات؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في المرضى الذين يعانون من ضعف العضلات الشديد (الوهن العضلي الوبيل)، يمكن أن يؤدي الاستخدام المتزامن للستيرويدات القشرية ومثبطات الكولينستريز، مثل نيوستجمين وبيريدوستجمين، إلى تحفيز حدوث نوبة وهن عضلي؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لمكافحة ارتفاع ضغط الدم (ضغط الدم المرتفع)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن تزداد سمية الجليكوزيدات القلبية (الأدوية التي تُستخدم لعلاج القلب، مثل ديجوكسين) عند استعمال الستيرويدات القشرية معها في نفس الوقت؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإستروجينات (بما في ذلك موانع الحمل التي تؤخذ عن طريق الفم المحتوية على إستروجين): قد يزيد الإستروجين من تأثيرات هيدروكورتيزون. وقد يكون من الضروري تعديل جرعة <strong>سولوكورتيف</strong> إذا أضيفت الإستروجينات إلى خطة العلاج أو أزيلت منها؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن تثبط الستيرويدات القشرية جزئيًا تأثير بعض المنتجات الدوائية المُستخدمة في التخدير، وخاصةً الحاصرات العصبية العضلية المكونة أساسًا من الكورار؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن تزيد الستيرويدات القشرية من الآثار الجانبية لمحاكيات الودي، مثل سالبيوتامول (دواء يُستخدم لعلاج الربو، إلى جانب حالات أخرى)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى، بما في ذلك، الباربيتيورات، وفينيل بيوتازون، وميثوتريكسات.</p><p dir="RTL">يمكن أن يزيد العلاج بالستيرويدات القشرية المتزامن من فعالية مضادات التخثر الكومارينية وينبغي أن تتم مراقبة مؤشر التخثر (INR) أو زمن البروثرومبين بشكل دقيق لتجنب حدوث نزيف تلقائي.</p><p dir="RTL"><strong>تناول سولوكورتيف مع الطعام والشراب</strong></p><p dir="RTL">لا ينطبق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">يمكن استخدام هذا الدواء أثناء الحمل فقط عندما تكون هناك ضرورة واضحة لذلك. إذا أصبحتِ حاملًا أثناء تناول هذا الدواء، فأخبري طبيبكِ فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم استخدام هذا الدواء أثناء الرضاعة الطبيعية، إلا إذا أخبركِ طبيبكِ بغير ذلك. يتم إفراز الستيرويدات القشرية في لبن الثدي لدى البشر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملًا أو تُرضعين رضاعة طبيعية، أو إذا كنتِ تعتقدين أنكِ قد تكونين حاملًا أو كنتِ تخططين للحمل، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير سولوكورتيف على القيادة واستخدام الآلات</strong></p><p dir="RTL">على الرغم من أن مشكلات الرؤية لا تحدث كأثر جانبي إلا في حالات نادرة، ينبغي أن تكون على علم بأن هناك احتمالًا لحدوثها وينبغي اتخاذ الحذر الواجب إذا كان يتعين عليك قيادة مركبات و/أو تشغيل آلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات سولوكورتيف</strong></p><p dir="RTL"><strong>يحتوي سولوكورتيف على الصوديوم</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp; </strong>يحتوي مسحوق ومذيب سولوكورتيف ۱۰۰ ملجم لتحضير محلول للحقن على أقل من ۱ مليمول (۲٣ ملجم) من الصوديوم لكل قارورة Act-O-Vial، أي أنه يعد &quot;خاليًا من الصوديوم&quot; تقريبًا.</p><p dir="RTL"><strong>-&nbsp;&nbsp; </strong>يحتوي مسحوق ومذيب سولوكورتيف ۲٥<strong>۰</strong> ملجم لتحضير محلول للحقن على ٢٥٫٣ ملجم من الصوديوم (المكون الأساسي لملح الطهي/الطعام) لكل Act-O-Vial. وهذا يكافئ ١٫٢٧ ٪ من الحد الأقصى للمدخول الغذائي من الصوديوم الموصى به للبالغين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على استخدام هذا الدواء تمامًا كما أوصى طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا مما يجب عليك فعله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم إعطاء سولوكورتيف عن طريق الحقن في العضل أو الوريد، أو عن طريق التسريب الوريدي.</p><p dir="RTL">تعتمد الجرعة ومدة العلاج على خصائص مرضك. سيحدد طبيبك الجرعة التي ينبغي عليك تناولها من هذا الدواء ومدة استعماله. احرص دائمًا على استخدام هذا الدواء تمامًا كما أخبرك طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من سولوكورتيف</strong></p><p dir="RTL">لا تسبب الجرعة المفرطة الحادة من هذا الدواء أي ظواهر مرئية (واضحة) على الفور. إلا أن الجرعة المفرطة المزمنة تتسبب في ظهور أعراض نمطية مثل، استدارة الوجه مثل القمر والتورم واحتباس الماء.</p><p dir="RTL">إذا استخدمت كمية أكبر من اللازم من سولوكورتيف، فتواصل فورًا مع طبيبك أو الصيدلي أو مركز مكافحة السموم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة سولوكورتيف</strong></p><p dir="RTL">بما أنك ستتلقى هذا العلاج تحت إشراف طبي دقيق، فمن غير المرجح أن يتم نسيان جرعة ما. وعلى الرغم من ذلك، إذا كنت تعتقد أن ذلك قد حدث، فأخبر طبيبك أو الصيدلي.</p><p dir="RTL"><strong>التوقف عن تناول سولوكورتيف</strong></p><p dir="RTL">سوف يحدد طبيبك المدة التي ينبغي عليك الاستمرار في تناول هذا الدواء خلالها. في حالة إيقاف العلاج طويل الأمد، يوصى بوجود متابعة طبية وسيتم التقليل التدريجي للدواء قبل الإيقاف. في هذه الحالة، سيتأكد طبيبك من أن غددك الكظرية تنتج ما يكفي من الستيرويدات القشرية. تتمثل علامات عدم وجود كمية كافية من الستيرويدات القشرية في الإرهاق الخطير (الوهن)، والدوار عند الانتقال من وضع الاستلقاء إلى وضع الوقوف (انخفاض ضغط الدم الانتصابي)، والاكتئاب.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">إذا كان لديك أي أسئلة إضافية بشأن استخدام هذا الدواء، فاطلب المزيد من المعلومات من طبيبك أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، من الممكن أن يسبب هذا الدواء آثارًا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تنتمي إلى إحدى المجموعات الخاصة المُعرضة للخطر، فسيقوم طبيبك بمراقبتك بانتظام (انظر القسم ۲ &quot;تحذيرات واحتياطات للاستخدام&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يسبب هذا الدواء، في حالات نادرة، تفاعل حساسية خطيرًا، وقد يكون مميتًا (التأق). إذا تعرضت لبدء سريع لأعراض تتمثل في صعوبات التنفس وتورم الوجه والحلق والتوعك العام (الصدمة)، <strong>فاتصل بطبيب على الفور.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تُعد الآثار الجانبية التي يمكن أن تحدث عند استخدام هذا الدواء هي نفسها بالنسبة لجميع القشرانيات السكرية. ونادرًا ما تحدث تلك الآثار أثناء العلاجات قصيرة الأمد. قد يزداد خطر حدوث الآثار الجانبية غير المرغوب فيها عند استعمال القشرانيات السكرية بجرعات عالية أو لفترة طويلة. فيما يلي قائمة بالآثار الجانبية الرئيسية التي قد تحدث، إلا أن معدل حدوثها غير معروف:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى وتفشي الأمراض: حجب الإصابة بحالات العدوى، إعادة تنشيط الدرن أو أي عدوى كامنة أخرى، العدوى الانتهازية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأورام الخبيثة وغير المحددة (بما في ذلك التكيسات والسلائل): ساركومة كابوزي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الجهاز المناعي: تفاعلات حساسية (على سبيل المثال الانقباض التشنجي في القصبات، تورم الحنجرة، ارتيكاريا)، تغير نتائج اختبارات الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الغدد الصماء: متلازمة كوشينج (السمنة المزمنة مع وجه متورم وأحمر يشبه &quot;القمر&quot;)، اضطرابات في توازن العمل بين الغدد المفرزة للقشريات السكرية الطبيعية والغدد التي تتحكم بها هذه الهرمونات، مثل الغدة النخامية (تثبيط المحور النخامي الكظري).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات الأيضية واضطرابات التغذية: احتباس الصوديوم، احتباس السوائل، فقدان البوتاسيوم (مما قد يؤدي إلى زيادة قلوية الدم بسبب نقص بوتاسيوم الدم)، اضطرابات في امتصاص السكر (إعادة تنشيط لداء السكري الكامن، تغير مستوى تحمل الجلوكوز).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات النفسية: تغيرات في المزاج أو الشخصية، النشوة، الأرق، الاكتئاب الشديد، تفاقم بعض المشكلات النفسية الموجودة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات العصبية: زيادة الضغط في القحف، الدوخة، النوبات، الورم الشحمي فوق الجافية.</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>اضطرابات العين: إعتام عدسة العين، الزرق (مع خطر إصابة الأعصاب البصرية)، عدوى العين، بروز العينين (جحوظ العين)، خطر حدوث انثقاب في القرنية في حالات الحزام الناري البسيط بالعين، اعتلال المشيمية والشبكية المصلي المركزي (وهو مرض يصيب شبكية العين)، تغيم الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الاضطرابات القلبية: فشل القلب الاحتقاني لدى المرضى المعرضين لخطر الإصابة، واضطراب ضربات القلب، وتوقف القلب، وزيادة سمك عضلة القلب (اعتلال عضلة القلب التضخمي) في الأطفال المبتسرين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات الوعائية: تكون جلطات الدم في الأوعية الدموية (الخثار)، ارتفاع ضغط الدم أو انخفاض ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الدم: زيادة في أعداد خلايا الدم البيضاء في الدم (كثرة الكريات البيضاء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات التنفسية: الانصمام الرئوي (انسداد وعاء دموي في الرئتين)، &quot;متلازمة اللهاث&quot; (وهي حالة تنفسية تتميز باللهاث المستمر).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات المعدية المعوية: قرحة المعدة المصحوبة بخطر الانثقاب والنزيف (النزف)، النزف في المعدة، انثقاب الأمعاء، التهاب البنكرياس أو المريء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الجلد: نزيف بسيط تحت الجلد (حبر)، تكدم، ضمور الجلد (ترقق وهشاشة الجلد)، احمرار الوجه (بقع حمراء بالوجه)، زيادة التعرق، حب الشباب، علامات تمدد الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات العضلية والعظمية: الضعف، أو الألم أو التهاب العضلات، فقدان الكالسيوم من العظم (هشاشة العظام)، النخر (تلف الأنسجة) المرتبط بالتمزق الموضعي للأوعية الدموية، نخر العظم (تلف نسيج العظم)، الكسور، بطء النمو في الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الأعضاء التناسلية والثدي: عدم انتظام الدورة الشهرية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات العامة وحالات موضع الاستعمال: تأخر الالتئام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاختبارات والتحاليل: زيادة الضغط داخل العين، الاضطرابات المرتبطة بامتصاص السكريات (انخفاض القدرة على تحمل الكربوهيدرات)، تزايد الحاجة إلى الأنسولين أو الأدوية الخافضة لسكر الدم لدى المصابين بالسكري، فقدان البوتاسيوم، نقص النيتروجين (التوازن السلبي للنيتروجين)، فقدان الكالسيوم، تغيرات في نتائج اختبارات وظائف الكبد، زيادة الوزن.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الآفات وحالات التسمم والمضاعفات الإجرائية: كسور الفقرات الانضغاطية، تمزق الأوتار (خاصة وتر أخيل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كثرة كريات الدم البيضاء</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية </strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي. يتضمن ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال: ۱۹۹۹۹</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa/&lrm;&nbsp;&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى:</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحفظ عند درجة حرارة اقل من ۳۰ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المحلول المحضر:</p><p dir="RTL">يحفظ بعيدًا عن الضوء ودرجات التجمد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ينبغي استخدام المحلول المُحضّر من مسحوق ومذيب سولوكورتيف المُخصصين لتحضير محلول للحقن، والموجودين في قارورة من نوع Act-O-Vial، بعد التحضير يستخدم على الفور</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المُوضح على العبوة الكرتونية بعد الرمز &quot;<strong>EXP</strong>&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">صلاحية المستحضر:</p><p dir="RTL">- سولوكورتيف ۱۰۰ ملجم: مسحوق ومذيب لمحلول الحقن (قارورة Act-O-Vial): ۲٤ شهرًا.</p><p dir="RTL">- سولوكورتيف ۲٥۰ ملجم: مسحوق ومذيب لمحلول الحقن (قارورة Act-O-Vial): ۳۰ شهرًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو في المخلفات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي هيدروكورتيزون.</p><p dir="RTL">توجد هذه المادة في صورة هيدروكورتيزون سكسينات الصوديوم (۱۳۳,٦٧ ملجم و۳۳٤,۱۸ ملجم)، وهو ما يكافئ ۱۰۰ ملجم أو ۲<strong>٥</strong>۰ ملجم من هيدروكورتيزون، على التوالي.<u> </u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">مسحوق ومذيب سولوكورتيف ۱۰۰ ملجم، ۲٥۰ ملجم لتحضير محلول للحقن:</p><p dir="RTL">- المسحوق المُخصص لتحضير محلول للحقن: (الحجيرة السفلى من القارورة Act-O-Vial): أحادي هيدرات فوسفات أحادي الصوديوم / فوسفات ثنائي الصوديوم لا مائي وهيدروكسيد الصوديوم. (انظر القسم ٢ &quot;يحتوي سولوكورتيف على الصوديوم&quot;)</p><p dir="RTL">- المذيب المُخصص لتحضير محلول للحقن: (الحجيرة العليا من القارورة Act-O-Vial): ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">صُنع سولوكورتيف ليُستخدم كمسحوق ومذيب لتحضير محلول للحقن في قارورات Act-O-Vial مزدوجة الحجيرات، مما يسمح بإعداد محلول الحقن بصورة بسيطة وفورية. يُعد المحلول المحضر من سولوكورتيف مخصصًا ليتم إعطاؤه عن طريق الوريد والعضل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">العبوات:</p><p dir="RTL">مسحوق ومذيب سولوكورتيف ۱۰۰ ملجم و۲٥۰ ملجم لتحضير محلول للحقن - قارورة من نوع Act-O-Vial.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك تصريح التسويق</strong></p><p dir="RTL">PFIZER S.A., Boulevard de la Plaine 17, 1050 Brussels, Belgium، بلجيكا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجهة المصنعة</strong></p><p dir="RTL">Pfizer Manufacturing Belgium NV, Rijksweg 12, 2870 Puurs, Belgium، بلجيكا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أغسطس/آب ٢٠٢١.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solu-Cortef 100 mg Powder and solvent for solution for injection
Solu-Cortef 250 mg Powder and solvent for solution for injection

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The active substance of Solu-Cortef is hydrocortisone. 
This is present in the form of hydrocortisone sodium succinate (133.67 mg and 334.18 mg), respectively equivalent to 100 mg and 250 mg of hydrocortisone.  

Excipient with known effect:
Solu-Cortef 250 mg Powder and solvent for solution for injection contains 25.3 mg sodium per Act-O-Vial.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for solution for injection 

Solu-Cortef contains lyophilized hydrocortisone sodium succinate for intravenous and intramuscular administration. This highly concentrated aqueous solution will rapidly elevate the blood level. 


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glucocorticoids should only be considered as a purely symptomatic treatment, unless in case of some endocrine disorders, where they are used as substitution treatment.</p><p>&nbsp;</p><p>ENDOCRINE DISORDERS</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Primary or secondary adrenocortical insufficiency</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Acute adrenocortical insufficiency</p><p>For these indications, hydrocortisone or cortisone are the medicines of first choice; where applicable, synthetic analogues can be combined with mineral corticoids; supplementation with mineral corticoids is particularly important in children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Prior to surgical operations and in the event of serious illness or trauma or, in patients suffering from known adrenocortical insufficiency or in the event of doubtful adrenocortical reserve</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Shock unresponsive to conventional therapy when adrenocortical insufficiency is present or presumed</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Congenital adrenal hyperplasia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Nonsuppurative thyroiditis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Hypercalcaemia associated with cancer</p><p>&nbsp;</p><p>NON-ENDOCRINE DISORDERS</p><p>1.&nbsp;&nbsp;&nbsp; <u>Allergic disorders</u><br />Control of severe or incapacitating allergic conditions not responding to adequate conventional treatments in:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Serum sickness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Bronchial asthma</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Drug hypersensitivity reactions</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Contact dermatitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Atopic dermatitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Urticarial transfusion reactions</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Quincke&rsquo;s edema (epinephrine is the drug of first choice)</p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp; <u>Respiratory disorders</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Symptomatic pulmonary sarcoidosis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Loeffler&#39;s syndrome not responding to standard treatment</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Berylliosis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous drugs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Aspiration pneumonitis</p><p>&nbsp;</p><p>3.&nbsp;&nbsp;&nbsp; <u>Hematologic disorders</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Idiopathic thrombocytopenica purpura in adults (intravenous administration only; intramuscular administration is contraindicated)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Secondary thrombocytopenia in adults</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Acquired (autoimmune) hemolytic anemia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Erythroblastopenia (aplastic anemia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Congenital hypoplastic anemia</p><p>&nbsp;</p><p>4.&nbsp;&nbsp;&nbsp; <u>Neoplastic disorders</u><br />For palliative management of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Leukaemias and lymphomas in adults</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Acute childhood leukaemia</p><p>&nbsp;</p><p>5.&nbsp;&nbsp;&nbsp; <u>Medical emergencies</u><br />Solu-Cortef is useful in the treatment of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Shock not responding to the standard therapy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Acute allergic disorders (status asthmaticus, anaphylactic reactions, insect bites, etc.)</p><p>&nbsp;</p><p>Although there are no well controlled (double‑blind with placebo) clinical trials, data from experimental animal models indicate that corticoids may be useful in shock states in which standard therapy (e.g. fluid replacement, etc.) has not been effective. See also section 4.4 &quot;Special warnings and precautions for use&quot;.</p><p>&nbsp;</p><p>6.&nbsp;&nbsp;&nbsp; <u>Other disorders</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Tuberculous meningitis with subarachnoid block or impending block when used concurrently with adequate antituberculous chemotherapy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Trichinosis with neurologic or myocardial involvement</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Intravenous injection is the method of first choice for initial treatment of emergency cases. A longer-acting injectable or oral preparation must be considered after this initial period.<br />The duration of the intravenous administration depends on the dose; it can vary from 30 seconds (100 mg for example) to 10 minutes (500 mg or more, for example).<br />&nbsp;</p><p>Treatment with high doses of corticosteroids may generally be continued only until the patient&#39;s condition has stabilized (usually not longer than 48 to 72 hours).</p><p>&nbsp;</p><p>If a treatment with high doses of hydrocortisone needs to be continued for longer than 48 to 72 hours hypernatriaemia can occur. In that case it may be desirable to replace Solu-Cortef by a corticosteroid preparation such as methylprednisolone sodium succinate, which causes little or no sodium retention.</p><p>&nbsp;</p><p>The initial dose of Solu-Cortef is 100 mg to 500 mg or more, depending on the severity of the condition. This dose may be repeated every 2, 4 or 6 hours if the clinical condition of the patient requires it.</p><p>&nbsp;</p><p>Corticosteroid therapy is an adjuvant; it does not replace conventional treatment.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The dosage of Solu-Cortef in paediatrics is determined more by the seriousness of the disorder and the patient&#39;s response than by the patient&#39;s age or bodyweight. The doses may be reduced but must never amount to less than 25 mg per day.<br />&nbsp;</p><p><u>Method of administration</u></p><p>Solu-Cortef can be administered in intramuscular or intravenous injection or in intravenous infusion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
Systemic fungal infections.
Administration of vaccines based on live attenuated virus is contra-indicated in patients receiving immunosuppressive doses of corticosteroids.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp; Special risk groups:</p><p>Patients belonging to the following risk groups should be treated under close medical supervision and for the shortest possible period:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Children and adolescents: growth retardation can occur in children receiving long-term treatment with glucocorticoids in divided daily doses. Such a regimen is justified only in very severe indications. Growth and development should be closely monitored in infants and children receiving long-term corticosteroid treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Diabetics: signs of latent diabetes mellitus or increased requirement of insulin or oral hypoglycaemic agents.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Hypertensive patients: aggravation of arterial hypertension.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Patients with osteoporosis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Patients with active or latent peptic ulcer, diverticulitis, recent intestinal anastomoses, non-specific ulcerative colitis if there is a risk of perforation and abscess or other pyogenic infections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Patients with a predisposition for thromboembolism. Thrombosis, including venous thromboembolism, has been reported with corticosteroids. As a result, corticosteroids should be used with caution in patients who have or may be predisposed to thromboembolic disorders.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Patients with myasthenia gravis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Patients with renal insufficiency</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Patients with a history of psychiatric disease: existing emotional instability and psychotic tendencies may be aggravated by corticosteroids. Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, sullen temper, personality disorders and severe depression to frank psychotic manifestations:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Patients with some infections such as tuberculosis: in active tuberculosis the use of Solu-Cortef should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used in conjunction with appropriate antituberculous chemotherapy. Patients with latent tuberculosis or tuberculin reactivity should be monitored closely during corticotherapy to detect possible reactivation of the disease. During prolonged corticosteroid therapy these patients should receive chemoprophylaxis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Patients with some viral conditions such as herpes and shingles with ocular symptoms: glucocorticoids should be used with caution in case of ocular herpes simplex because of the risk of corneal perforation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Patients with Epilepsy</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible effects of corticosteroids include adrenal suppression, decrease in bone mineral density, cataract and glaucoma.&nbsp;</p><p>Corticosteroid therapy has been associated with central serous chorioretinopathy, which can lead to retinal detachment.</p><p>Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.<br />Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used. It is important that the dose of corticosteroid is titrated to the lowest dose at which effective control of symptoms is achieved.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cases of epidural lipomatosis have been reported in patients receiving corticosteroids, usually at high doses over the long-term.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Although brief treatments with high doses of corticosteroids are seldom accompanied by undesirable side-effects, stomach ulcers can occur. Prophylactic use of antacids may be indicated.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting glucocorticosteroids before, during and after the stressful situation is indicated.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients subjected to severe stress after corticosteroid therapy must be kept under close observation for symptoms of adrenocortical insufficiency.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Glucocorticosteroids may mask some signs of infection and new infections may appear during their use. There may be decreased resistance and inability to localize infection when corticosteroids are used. Systemic infections involving bacteria, viruses, moulds, protozoa or worms, can be associated with corticosteroid treatment, either alone or in combination with other immunosuppressant substances which have an effect on cell immunity, humoral immunity or neutrophil activity. These infections may be of a moderate or severe nature and in some cases fatal. The number of infections rises with increasing corticoid dosage.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hydrocortisone can lead to increase in blood pressure, water- and salt-retention and increased potassium excretion. A sodium-free diet and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administration of attenuated live vaccines is contraindicated in patients being treated with immunosuppressant doses of corticosteroids. Inactivated and biogenetically obtained vaccines may be administered however to these patients. However the response to such vaccines may be diminished or they can even be ineffective. The necessary immunization procedures should be however undertaken in patients being treated with non-immunosuppressant doses of corticosteroids.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Because rare instances of anaphylactic (e.g. bronchospasm) reactions have occurred in patients receiving parenteral corticosteroid therapy, appropriate precautionary measures should be taken prior to administration of this product, especially when the patient has a history of allergy to this type of product.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drug‑induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There is an enhanced effect of glucocorticosteroids on patients with hypothyroidism and in those with cirrhosis.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Although no recent studies have been conducted with hydrocortisone, a study with methylprednisolone sodium succinate in septic shock indicated a higher mortality rate in a patient sub-group, namely those persons in whom an elevated serum creatinine level was found (&gt;2%) at the start of the study, or in patients who contracted a secondary infection after commencement of the therapy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The occurrence of acute myopathies is reported with the use of high doses of corticosteroids. These occur mostly in patients with neuromuscular transmission disorders (myasthenia gravis for example) or in patients undergoing simultaneous treatment with neuromuscular-inhibiting medication. (pancuronium, for example).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This acute myopathy can occur anywhere and can affect the eye and respiratory muscles and can result in quadriparesis. An increase in creatine kinase can be induced. Weeks or even years may pass after the corticosteroid therapy has stopped before a clinical improvement or cure takes place.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The occurrence of Kaposi sarcoma has been reported in patients treated with corticosteroids. Stopping of the corticosteroid therapy can bring about clinical remission.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A crisis of pheochromocytoma, which may be fatal, was reported after the administration of systemic corticosteroids. Corticosteroids may only be administered to patients with suspected or identified pheochromocytoma after an appropriate assessment of benefits/risks.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Systemic corticosteroids are not indicated for, and therefore should not be used to treat, traumatic brain injury. A multicentre study revealed an increased mortality at 2 weeks and 6 months after injury in patients administered methylprednisolone sodium succinate compared to placebo. A causal association with methylprednisolone sodium succinate treatment has not been established.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corticotherapy has to be considered when interpreting a whole series of biological tests and parameters (e.g. skin tests, thyroid hormone levels).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The duration of the treatment should in general be kept as short as possible. Medical surveillance is recommended during chronic treatment (see also section 4.2). The discontinuation of a chronic treatment should also occur under medical surveillance (gradual discontinuation, evaluation of the adrenocortical function). The most important symptoms of adrenocortical insufficiency are asthenia, orthostatic hypotension and depression.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection into the deltoid muscle should be avoided because of the high incidence of subcutaneous atrophy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side-effects (see section 4.5).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypertrophic cardiomyopathy was reported after administration of hydrocortisone to prematurely born infants, therefore appropriate diagnostic evaluation and monitoring of cardiac function and structure should be performed.</p><p><u>&nbsp;</u></p><p><em>Excipients information</em></p><p>Solu-Cortef 100 mg Powder and solvent for solution for injection contains less than 1 mmol sodium (23 mg), that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p><p>Solu-Cortef 250 mg Powder and solvent for solution for injection contains 25.3 mg sodium per Act-O-Vial equivalent to 1.27% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp; Simultaneous administration of liver enzyme-inducing medicines such as barbiturates, phenylbutazone, phenytoin, carbamazepin or rifampicin can accelerate metabolism and thus diminish the effect of corticosteroids.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Macrolides such as erythromycin and medicines such as ketoconazole can inhibit the metabolism of corticosteroids. Modification of the corticosteroid dose may be required to prevent overdosing.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Protease inhibitors (e.g. ritonavir, indinavir) and pharmacokinetic enhancers (e.g. cobicistat) inhibit CYP3A4 activity leading to a decreased hepatic clearance and increased plasma concentration of the corticosteroid. A dose adjustment of the corticosteroid may be required (see section 4.4).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Glucocorticosteroids can increase the renal clearance of chronic high dose salicylates. This can lead to lowered salicylate levels and to salicylate intoxication when the corticosteroid therapy is stopped.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Acetylsalicylic acid should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Corticoids can both reduce and raise the response to anticoagulants. Continuous monitoring of coagulation parameters is consequently necessary.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Combination of glucocorticosteroids with ulcerogenic drugs (e.g. salicylates and NSAIDs) increases the risk of gastrointestinal complications.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Combination of glucocorticosteroids with thiazide diuretics increases the risk of glucose intolerance.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Glucocorticosteroids can increase the requirements for insulin or oral hypoglycemic agents in diabetics.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Administration of attenuated live vaccines is contraindicated in patients being treated with immunosuppressant doses of corticosteroids. Inactivated and biogenetically obtained vaccines may be administered however to these patients. However the response to such vaccines may be diminished or they can even be ineffective. The necessary immunization procedures may be undertaken in patients being treated with non-immunosuppressant doses of corticosteroids.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Concomitant administration of glucocorticoids and cholinesterase inhibitors such as neostigmine and pyridostigmine may precipitate myasthenic crisis and the need for respiratory support should be anticipated in this situation.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; The intrinsic mineralocorticoid effect of hydrocortisone results in elevations of blood pressure and may result in increased requirements for antihypertensive agents.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; The toxicity of heart glycosides such as digoxin can increase during concomitant use with corticosteroids because of the intrinsic potassium-depleting effect of hydrocortisone.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Estrogens (including oral contraceptives containing estrogens): CYP3A4 inhibitor (and substrate): Estrogens may potentiate effects of hydrocortisone by increasing the concentration of transcortin and thus decreasing the amount of hydrocortisone available to be metabolized. Dosage adjustments of hydrocortisone may be required if estrogens are added to or withdrawn from a stable dosage regimen.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; If corticosteroids are administered concurrently with potassium-depleting diuretics, potassium should be monitored frequently.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Concomitant administration of methotrexate and corticosteroids can have synergistic effects on the disease state and permit reduction in corticosteroid dose.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Antagonism of the neuromuscular blocking effects of pancuronium and vecuronium has been reported in patients taking corticosteroids. Prolonged coadministration of these agents may increase the risk and/or severity of myopathy resulting in prolonged paralysis following discontinuation of the neuromuscular blocking agent</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Corticosteroids increase the number of beta receptors and so may increase sensitivity to &beta;<sub>2</sub>-receptor agonists.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Post-marketing surveillance reports indicate that the risk of tendon rupture may be increased in patients receiving fluoroquinolones and corticosteroids, especially in the elderly.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Corticosteroids readily cross the placenta. One retrospective study revealed an increased incidence in low birth weight in infants whose mothers had received corticosteroids.</p><p>&nbsp;</p><p>Though neonatal adrenocortical insufficiency is rare in infants who were exposed in utero to corticosteroids, infants born of mothers who have received substantial doses of glucocorticoids during pregnancy, should be carefully observed and evaluated for signs of adrenocortical insufficiency.</p><p>&nbsp;</p><p>Cases of cataract have been observed in infants born of mothers treated with long-term corticosteroids during pregnancy.</p><p>&nbsp;</p><p>In case of labour and delivery no effects are known.</p><p>Some animal studies have shown that corticosteroids when administered during pregnancy at high doses, may cause fetal malformations (see section 5.3).</p><p>&nbsp;</p><p>Since safety in pregnancy has not been adequately demonstrated, this medicine should not be used during pregnancy unless it is strictly necessary.<br />&nbsp;</p><p><u>Breast-feeding </u></p><p>Corticosteroids are excreted in breast milk.</p><p>There is no evidence that corticosteroids are carcinogenic, mutagenic or impair fertility.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Animal studies have shown that corticosteroids may impair fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Although visual disorders belong to the rare adverse reactions, caution is recommended by patients driving cars and/or using machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety profile</u></p><p>The following undesirable effects are typical for systemic corticosteroids.</p><p>Hypersensitivity reactions may occur at the beginning of treatment. Serious infections, including opportunistic infections, may also occur with corticosteroid treatment. Other undesirable effects include: seizures, pathological and vertebral compression fractures, peptic ulcers with perforation or haemorrhage, tendon rupture, psychic and psychotic disorders, cushingoid disorders, decreased glucose tolerance, increased intraocular pressure, subcapsular cataract, atrophy of the skin and fluid retention.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p><strong>&nbsp;</strong></p><p>General side effects may be observed. They rarely occur during treatment of very short duration, but must nonetheless be sought attentively, a precaution common to all corticosteroids and not specific to a particular product. Glucocorticoids can have the following general adverse events:<br />&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td colspan="2" style="vertical-align:top"><p>Side effects</p></td></tr><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Frequency unknown</p><p>(cannot be estimated from the available data)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong><em>Infections and infestations</em></strong></p></td><td style="vertical-align:top"><p>Masking of infections;</p><p>Opportunistic infections, ranging from mild to fatal, due to any pathogen, and at any location in the body;</p><p>Infection (activation of, including reactivation of tuberculosis).</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Benign, malignant and unspecified tumours (including cysts and polyps)</em></strong></p></td><td style="vertical-align:top"><p>Kaposi&#39;s sarcoma has been reported in patients treated with corticosteroids.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Blood and lymphatic system disorders</em></strong></p></td><td style="vertical-align:top"><p>Leukocytosis</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Immune system disorders</em></strong></p></td><td style="vertical-align:top"><p>Hypersensitivity reactions, including anaphylaxis and<br />anaphylactic reactions (bronchospasm, laryngeal oedema, urticaria);</p><p>Potential inhibition of skin test reactions</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Endocrine disorders</em></strong></p></td><td style="vertical-align:top"><p>Cushing&#39;s syndrome;</p><p>Inhibition of the pituitary-adrenal axis.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Metabolic and nutritional disorders</em></strong></p></td><td style="vertical-align:top"><p>Sodium retention;</p><p>Fluid retention;</p><p>Hypokalaemic alkalosis;</p><p>Impaired glucose tolerance;</p><p>Reactivation of latent diabetes mellitus.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Psychiatric disorders</em></strong></p></td><td style="vertical-align:top"><p>Psychiatric disorders or psychotic manifestations (euphoria, insomnia, changeable mood, changes in personality, severe depression, worsening of emotional instability, worsening of pre-existing psychotic behaviour).</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Nervous system disorders</em></strong></p></td><td style="vertical-align:top"><p>Increased intracranial pressure;</p><p>Benign intracranial hypertension;</p><p>Convulsions;</p><p>Dizziness;</p><p>Epidural lipomatosis.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Ocular disorders</em></strong></p></td><td style="vertical-align:top"><p>Prolonged use of glucocorticoids can lead to posterior subcapsular cataracts, glaucoma with potential damage to the ocular nerves, and may promote the development of secondary fungal or viral eye infections;</p><p>Glucocorticoids should be administered with caution in cases of ocular herpes simplex, due to the possibility of corneal perforation;</p><p>Exophthalmos;</p><p>Central serous chorioretinopathy;</p><p>Vision, blurred (see also section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Cardiac disorders</em></strong></p></td><td style="vertical-align:top"><p>Congestive heart failure (in susceptible patients), hypertrophic cardiomyopathy in prematurely born infants</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Vascular disorders</em></strong></p></td><td style="vertical-align:top"><p>Thrombosis, hypertension</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Respiratory, thoracic and mediastinal disorders</em></strong></p></td><td style="vertical-align:top"><p>Pulmonary embolism, Gasping syndrome (respiratory disorder characterized by a persistent gasping for breath).</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Gastrointestinal disorders</em></strong></p></td><td style="vertical-align:top"><p>Peptic ulcer (potentially with perforation and haemorrhage);</p><p>Gastric haemorrhage;</p><p>Pancreatitis;</p><p>Oesophagitis;</p><p>Intestinal perforation.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Skin and subcutaneous tissue disorders</em></strong></p></td><td style="vertical-align:top"><p>Petechiae;</p><p>Bruising;</p><p>Atrophy of the skin;</p><p>Thin and fragile skin;</p><p>Facial erythema;</p><p>Increased sweating;</p><p>Acne;</p><p>Stretch marks.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Musculoskeletal and connective tissue disorders</em></strong></p></td><td style="vertical-align:top"><p>Steroidal myopathy;</p><p>Muscular weakness;</p><p>Osteonecrosis;</p><p>Aseptic necrosis;</p><p>Osteoporosis;</p><p>Pathological fractures;</p><p>Inhibition of growth in children.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Reproductive system and breast disorders</em></strong></p></td><td style="vertical-align:top"><p>Irregular menstruation</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>General disorders and anomalies at the site of administration</em></strong></p></td><td style="vertical-align:top"><p>Slowed healing of wounds</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Investigations</em></strong></p></td><td style="vertical-align:top"><p>Increased intraocular pressure;</p><p>Decreased glucose tolerance;</p><p>Increase in requirement for insulin or oral hypoglycaemic agents in diabetic patients;</p><p>Decreased serum potassium;</p><p>Negative nitrogen balance (due to protein catabolism);</p><p>Increase calcium excretion;</p><p>There may be a transient and moderate increase in ALT, ALS and blood alkaline phosphatase, with no apparent clinical syndromes, weight increased.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Lesions, toxicity and procedural complications</em></strong></p></td><td style="vertical-align:top"><p>Vertebral compression fractures;</p><p>Tendon tears (in particular, tearing of the Achilles tendon).</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><em>The following side effects may be observed in parenteral corticosteroid therapy:</em></strong></p><p>Anaphylactic or allergic reactions with or without circulatory collapse</p><p>Cardiac arythmias and cardiac arrest</p><p>Bronchospasm</p><p>Hypotension or hypertension</p><p>&nbsp;</p><p><strong><u>Pediatric population</u></strong></p><p>Frequency, type and severity of adverse reactions in children are expected to be the same as in adults.</p><p>&nbsp;</p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to their local country requirements.</p><p><strong>&nbsp;</strong></p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp; SFDA Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no clinical syndrome of acute overdosage with Solu-Cortef. Chronic overdosage induces typical Cushing symptoms. Hydrocortisone is dialyzable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The therapeutic activity of Solu-Cortef is qualitatively identical to that of hydrocortisone.</p><p>Pharmacotherapeutic group: glucocorticoids, ATC code: H02AB09</p><p>&nbsp;</p><p>Glucocorticoids diffuse across cell membranes and complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, bind to DNA (chromatin), and stimulate transcription of mRNA and subsequent protein synthesis of various enzymes thought to be ultimately responsible for the numerous effects of glucocorticoids after systemic use. Glucocorticoids not only have an important influence on inflammatory and immune processes, but also affect the carbohydrate, protein and fat metabolism. They also act on the cardiovascular system, the skeletal muscles and the central nervous system.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; <u>Effect on the inflammatory and immune process</u>:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; The anti‑inflammatory, immunosuppressive and anti‑allergic properties of glucocorticoids are responsible for most of the therapeutic applications. These properties lead to the following results:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; reduction of the immunoactive cells near the inflammation focus;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; reduced vasodilation;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; stabilization of the lysosomal membranes;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; inhibition of phagocytosis;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; reduced production of prostaglandines and related substances.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; <u>Effect on carbohydrate and protein metabolism</u>:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Glucocorticoids have a protein catabolic action. The liberated amino acids are converted into glucose and glycogen in the liver by means of the gluconeogenesis process. Glucose absorption in peripheral tissues decreases, which leads to hyperglycemia and glucosuria, especially in patients who are prone to diabetes.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; <u>Effect on lipid metabolism</u>:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Glucocorticoids have a lipolytic action. This lipolytic activity mainly affects the limbs. They also have a lipogenetic effect which is most evident on trunk, neck and head. All this leads to a redistribution of the fat deposits.</p><p>Maximum pharmacologic activity of corticosteroids lags behind peak blood levels, suggesting that most effects of the drugs result from modification of enzyme activity rather than from direct actions by the drugs.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After intramuscular administration of Solu-Cortef the peak serum levels are reached about 30 - 60 minutes after injection. The serum protein binding amounts to about 40 to 90 %. By far the greater part is eliminated after binding with a globulin (transcortin) and only a small quantity is bound to albumin. The free unbound fraction of the hormone determines the biological activity of the hormone while the bound fraction serves as reserve.</p><p>Hydrocortisone is metabolised principally in the liver. 22 - 30 % of intravenous and intramuscular administered doses are excreted via the urine within 24 hours.</p><p>As elimination from the bloodstream is practically complete after about 12 hours intravenous and intramuscular injections should be repeated every 4-6 hours if maintenance of a high blood-level is required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Conventional studies of safety pharmacology and repeated dose toxicity have identified no particular risk.&nbsp; Toxicities observed in repeated dose studies are those expected during continuous exposure to exogenous adrenal cortical steroids.</p><p>&nbsp;</p><p><u>Carcinogenicity: </u></p><p>Due to the indication of this medicinal product for treatments of short duration only, long-term studies to evaluate its carcinogenic potential in animals have not been conducted.</p><p><u>&nbsp;</u></p><p><u>Mutagenicity:</u></p><p>No potential for genetic or chromosomal mutation was identified in limited studies carried out in bacterial and mammalian cells.</p><p>&nbsp;</p><p><u>Reproductive toxicity:</u></p><p>It has been shown that corticosteroids administered to rats reduce fertility.</p><p>Corticosteroids have been shown to be teratogenic in many species after administration of doses equivalent to doses used in humans. In animal reproduction studies, glucocorticoids such as methylprednisolone were found to induce malformations (cleft palate, skeletal malformations) and slowed intrauterine growth.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Solu-Cortef 100 mg and 250 mg powder and solvent for solution for injection:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Powder for solution for injection (lower compartment of Act-O-Vial): Monobasic Sodium Phosphate Monohydrate ‑ Disodium Phosphate Anhydrous, and Sodium Hydroxide.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Solvent for solution for injection (upper compartment of Act-O-Vial): Water for Injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unreconstituted product: 
Do no use this product after the expiry date which is stated on the carton label after EXP:. The expiry date refers to the last day of that month.
Shelf life:
- Solu-Cortef 100 mg powder and solvent for solution for injection (Act-O-Vial): 24 months.
- Solu-Cortef 250 mg powder and solvent for solution for injection (Act-O-Vial): 30 months.

Solution reconstitued with Act-O-Vial: the solution is to be used immediately after reconstitution. 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Unreconstituted product</u>:</p><p>Store Below 30 &deg;C.</p><p><u>&nbsp;</u></p><p><u>Reconstitued solution:</u></p><p>- Act-O-Vial: do not freeze and protect from light.</p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pack sizes: Solu-Cortef 100 mg and 250mg, powder and solvent for solution for injection: 1 Act-O-Vial</p><p>*Act-O-Vial: a 2 compartments vial which allows a simple and instant preparation of the sterile solution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Preparation of solutions:</u></em></p><p>Parenteral medicines must be inspected visually before administration for the possible presence of particles and discoloration.</p><p><u>&nbsp;</u></p><p><u>Directions for use of the Act-O-Vial</u></p><p>1.&nbsp;&nbsp;&nbsp; Press down the plastic cap to force solvent into the lower compartment.</p><p>2.&nbsp;&nbsp;&nbsp; Gently agitate to complete dissolving.</p><p>3.&nbsp;&nbsp;&nbsp; Remove plastic protective strip.</p><p>4.&nbsp;&nbsp;&nbsp; Sterilize the rubber stopper.</p><p>5.&nbsp;&nbsp;&nbsp; Insert needle squarely through center of stopper until tip is just visible in the lower compartment. Turn the vial and draw up the required dose.</p><p><u>&nbsp;</u></p><p><u>Intravenous or intramuscular injection:</u></p><p>Act-O-Vial pack sizes: prepare the solution as described above.</p><p>pack sizes with powder for solution injection: Add the required amount of diluent (bacteriostatic water for injection, isotonic saline solution...) to the vial containing sterile powder under aseptic conditions.</p><p><u>&nbsp;</u></p><p><u>I</u><u>ntravenous</u><u> infusion:</u></p><p>First prepare the solution as described above.</p><p>The 100 mg solution may then be added to 100 - 1000 ml aqueous 5 % glucose solution (or isotonic saline solution or 5 % glucose in an isotonic saline solution if the patient is not on a sodium diet).</p><p>&nbsp;</p><p>The 250 mg solution may be added to 250 - 1000 ml.</p><p>&nbsp;</p><p>In cases where administration of small volumes of liquid is desired, 100 mg to 3000 mg Solu-Cortef may be added to 50 ml of the above-mentioned diluents. The resulting solutions remain stable for at least 4 hours and may be administered either directly or by means of IV &quot;piggy-back&quot;.</p><p>&nbsp;</p><p>The pH of the reconstituted solution, prepared as described above, is between 7 and 8.</p><p>&nbsp;</p><p>Any unused medicine or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder
Pfizer S.A., 17 Boulevard de la Plaine, 1050 Bruxelles, Belgium.

Manufactured, Packed & Released by
Pfizer Manufacturing Belgium NV, Rijksweg 12, 2870 Puurs, Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>